Company | Name | Exchange | Sector | Industry | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
UCB | Brussels | Healthcare | Pharmaceuticals | €29.30B | 27.5x | 0.14 | €154.35 | 1.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 37.4% Upside | Upgrade to Pro+ | |
Tubize-Fin | Brussels | Healthcare | Pharmaceuticals | €5.44B | 60.4x | 29.61 | €122 | 1.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 49.5% Upside | Upgrade to Pro+ | |
Fagron | Brussels | Healthcare | Pharmaceuticals | €1.56B | 19.4x | 1.38 | €21.35 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 6.1% Upside | Upgrade to Pro+ | |
Hyloris | Brussels | Healthcare | Pharmaceuticals | €162.43M | -25.5x | €5.71 | -1.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
Biosenic | Brussels | Healthcare | Pharmaceuticals | €1.04M | -0x | -0 | €0.002 | -85% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ |